The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

The Effectiveness of Early Treatment with “Second-Line” Antirheumatic Drugs: A Randomized, Controlled Trial

Agnes van der Heide, MD; Johannes W.G. Jacobs, MD; Johannes W.J. Bijlsma, MD; Anton H.M. Heurkens, MD; Christina van Booma-Frankfort, MD; Maaike J. van der Veen, MD; Huub C.M. Haanen, MD; and Dick M. Hofman, MD
[+] Article, Author, and Disclosure Information

For a listing of additional authors and current author addresses, see end of text. Acknowledgments: The authors thank A. Algra, M. Boers, C. Cornelis, O. Huber-Bruning, E. Oostveen, and P.L.C.M. van Riel for their contributions to this article. Grant Support: Grant VR/235 from the Dutch League against Rheumatism (Het Nationaal Reumafonds). Requests for Reprints: Johannes W.G. Jacobs, MD, Department of Rheumatology F02.223, University Hospital Utrecht, PO Box 85500, 3508 GA Utrecht, the Netherlands. Current Author Addresses: Dr. van der Heide: Department of Public Health, Faculty of Medicine, Erasmus University, PO Box 1738, 3000 DR Rotterdam, the Netherlands.

Ann Intern Med. 1996;124(8):699-707. doi:10.7326/0003-4819-124-8-199604150-00001
Text Size: A A A

Objective: To compare two therapeutic strategies for patients with recent-onset rheumatoid arthritis.

Design: Open, randomized clinical trial.

Setting: Outpatient clinics of six clinical centers.

Patients: 238 consecutive patients with recently diagnosed rheumatoid arthritis.

Interventions: Delayed or immediate introduction of treatment with slow-acting antirheumatic drugs (SAARDs).

Measurements: Primary end points were functional disability, pain, joint score, and erythrocyte sedimentation rate at 6 and 12 months and progression of radiologic abnormalities at 12 months.

Results: Statistically significant advantages at 12 months for patients receiving the SAARD strategy (immediate treatment with SAARDs) with regard to all primary end points that may be clinically important are indicated by the differences in improvements from baseline and their 95% CIs. These differences were 0.3 (95% CI, 0.2 to 0.6) for disability (range, 0 to 3), 10 mm (CI, 1 to 19 mm) for pain (range, 0 to 100 mm), 39 (CI, 4 to 74) for joint score (range, 0 to 534), and 11 mm/h (CI, 3 to 19 mm/h) for erythrocyte sedimentation rate (range, 1 to 140 mm/h), all in favor of SAARD treatment. The SAARD strategy also appears to be advantageous at 6 months. Radiologic abnormalities progressed at an equal rate in the SAARD and the non-SAARD groups; the difference in progression (range, 0 to 448) was 1 (CI, − 3 to 5). Analyses were based on the intention-to-treat principle and thus included 29% of patients in the non-SAARD group who discontinued the non-SAARD treatment strategy; treatment was usually discontinued because of insufficient effectiveness. The SAARD strategy including two alternative SAARDs could not be continued by 8% of patients, usually because of adverse reactions.

Conclusions: Early introduction of SAARDs may be more beneficial than delayed introduction for patients with recently diagnosed rheumatoid arthritis.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $32.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.